18 and older, any sex, with NHL or Non Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants Experiencing Dose Limiting Toxicity EventsPrimary· 28 Days Post FT596 infusion
The component I design (FT596 on day 30) will continue until the MTD is declared or until the first dose is declared to be above MTD. The component I dose limiting toxicity (DLT) is defined as any of the following events within 28 days after the FT596 dosing based on CTCAE v5:Grade 4 hematologic toxicity lasting \> 7 days ,Grade 4 non-hematologic toxicity ,Grade ≥3 Infusion Related Reaction, Grade 2 acute GVHD that requires steroid therapy \>7 days or progression after 3 days of steroids or has partial response after 14 days of treatment, Grade ≥3 acute GVHD, Grade 4 cytokine release syndrome
Group
Value
95% CI
FT596 + Rituximab Dose Level 1: 9x10^7 Cells/Dose
0
FT596 + Rituximab Dose Level 2: 3x10^8 Cells/Dose
0
FT596 + Rituximab Dose Level 3: 9x10^8 Cells/Dose
0
Number of Participants Experiencing Adverse EventsSecondary· 1 year post FT596 infusion
Number of participants experiencing adverse events related to FT596 post auto-HSCT in combination with rituximab
Group
Value
95% CI
FT596 + Rituximab Dose Level 1: 9x10^7 Cells/Dose
3
FT596 + Rituximab Dose Level 2: 3x10^8 Cells/Dose
0
FT596 + Rituximab Dose Level 3: 9x10^8 Cells/Dose
1
Percentage of Participants With Relapse/ProgressionSecondary· 1 year post auto HSCT
Percentage of participants experiencing progression or relapse at 12 months post auto HSCT
Group
Value
95% CI
FT596 + Rituximab Dose Level 1: 9x10^7 Cells/Dose
67
22 – 100
FT596 + Rituximab Dose Level 2: 3x10^8 Cells/Dose
33
0 – 77
FT596 + Rituximab Dose Level 3: 9x10^8 Cells/Dose
0
0 – 100
Number of Participants Experiencing Non-relapse Mortality Incidents at 100 Days Post HSCTSecondary· 100 days post HSCT
Number of participants experiencing non-relapse mortality at 100 days post auto-HSCT.
Group
Value
95% CI
FT596 + Rituximab Dose Level 1: 9x10^7 Cells/Dose
0
FT596 + Rituximab Dose Level 2: 3x10^8 Cells/Dose
0
FT596 + Rituximab Dose Level 3: 9x10^8 Cells/Dose
0
Percentage of Non-relapse Mortality Incidents at One Year Post HSCTSecondary· one year post auto-HSCT
Percentage of participants experiencing non-relapse mortality at one year post auto-HSCT.
Group
Value
95% CI
FT596 + Rituximab Dose Level 1: 9x10^7 Cells/Dose
67
5 – 95
FT596 + Rituximab Dose Level 2: 3x10^8 Cells/Dose
100
0 – 100
FT596 + Rituximab Dose Level 3: 9x10^8 Cells/Dose
100
0 – 100
Progression-Free Survival 12 Months Post Auto-HCTSecondary· 12 Months Post Auto-HCT
Progression-Free Survival 12 Months Post Auto-HCT
Group
Value
95% CI
FT596 + Rituximab Dose Level 1: 9x10^7 Cells/Dose
33
1 – 77
FT596 + Rituximab Dose Level 2: 3x10^8 Cells/Dose
67
5 – 95
FT596 + Rituximab Dose Level 3: 9x10^8 Cells/Dose
100
0 – 100
Adverse events — posted to ClinicalTrials.gov
Time frame: 1 year.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This is a Phase I multi-center study to evaluate the safety of FT596 when given with rituximab as relapse prevention in patients who have undergone an autologous hematopoietic stem cell transplant (auto-HSCT) for diffuse large or high-grade B cell lymphoma.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT04245722 — FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
· Phase 1
· terminated
Other recruiting trials for NHL
Currently open trials in the same condition.
NCT07161713 — SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors
· NA
· recruiting
NCT06731699 — A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS
· Phase 1
· recruiting
NCT06119685 — IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
· Phase 1, PHASE2
· recruiting
NCT04440436 — Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients
· Phase 1, PHASE2
· recruiting
NCT03789240 — Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
· Phase 2
· active not recruiting
Other Masonic Cancer Center, University of Minnesota trials
Trials by the same sponsor.
NCT06772090 — Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies
· NA
· not yet recruiting
NCT06584929 — Rural Smoking Cessation
· NA
· not yet recruiting
NCT07153016 — LEgal Guidance and AdvocaCY for CAREgivers (LEGACY CARE): A Pilot Clinical Trial for Caregivers of Persons With Colorect
· NA
· recruiting
NCT06792825 — HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
· Phase 2
· recruiting
NCT07070726 — UNTOLD Ovarian Cancer Unmet Needs Survey
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Masonic Cancer Center, University of Minnesota
Last refreshed: 9 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04555811.